6.665
Schlusskurs vom Vortag:
$6.58
Offen:
$6.51
24-Stunden-Volumen:
948.23K
Relative Volume:
0.65
Marktkapitalisierung:
$927.27M
Einnahmen:
$62.04M
Nettoeinkommen (Verlust:
$-533.34M
KGV:
-1.7003
EPS:
-3.92
Netto-Cashflow:
$-473.07M
1W Leistung:
+18.38%
1M Leistung:
+29.92%
6M Leistung:
+22.74%
1J Leistung:
-23.57%
Vir Biotechnology Inc Stock (VIR) Company Profile
Firmenname
Vir Biotechnology Inc
Sektor
Branche
Telefon
415-906-4324
Adresse
1800 OWENS STREET, SAN FRANCISCO, CA
Vergleichen Sie VIR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
VIR
Vir Biotechnology Inc
|
6.665 | 915.44M | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.54 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.82 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.91 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
891.83 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.92 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-03 | Eingeleitet | Evercore ISI | Outperform |
| 2025-08-27 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-01-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-09-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-03-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-02-21 | Hochstufung | Goldman | Neutral → Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | Eingeleitet | SVB Leerink | Outperform |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-03-03 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-09-22 | Herabstufung | Goldman | Buy → Neutral |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-01-27 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-09-14 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-11 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-08-20 | Eingeleitet | Needham | Buy |
| 2020-03-19 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-03-13 | Herabstufung | Goldman | Buy → Neutral |
| 2020-02-27 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-11-14 | Eingeleitet | Robert W. Baird | Neutral |
| 2019-11-05 | Eingeleitet | Barclays | Overweight |
| 2019-11-05 | Eingeleitet | Cowen | Outperform |
| 2019-11-05 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Vir Biotechnology Inc Aktie (VIR) Neueste Nachrichten
Vir Biotechnology stock gets positive readthrough from Mirum’s Bluejay deal By Investing.com - Investing.com India
After Losing 25% in the Past Year, Vir Biotechnology, Inc. (NASDAQ:VIR) Institutional Owners Must Be Relieved by the Recent Gain - 富途牛牛
Vir Biotechnology (VIR) Gains Positive Outlook Amid Industry Acq - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Shares Gap UpShould You Buy? - MarketBeat
Vir Biotechnology Insiders Sold US$1.1m Of Shares Suggesting Hesitancy - simplywall.st
Can Vir Biotechnology (NASDAQ:VIR) Afford To Invest In Growth? - Yahoo Finance
Is Alnylam Pharmaceuticals a Millionaire Maker? - The Motley Fool
Is Vir Biotechnology Inc a good long term investmentRSI Overbought/Oversold & Rapid Wealth Accumulation - earlytimes.in
Insider Selling: Vir Biotechnology (NASDAQ:VIR) Major Shareholder Sells 191,854 Shares of Stock - MarketBeat
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Nasdaq Index Fund Health Drive - Kalkine Media
Insider Selling: Vir Biotechnology (NASDAQ:VIR) Director Sells 22,000 Shares of Stock - MarketBeat
Vir Biotechnology, Inc. (VIR) Stock Forecasts - Yahoo! Finance Canada
Vir Biotechnology (NASDAQ:VIR) Shares Gap Down After Insider Selling - MarketBeat
What drives Vir Biotechnology Inc stock priceStochastic Oscillator Alerts & You’ve Never Seen Stock Picks Like These - earlytimes.in
Vir Biotechnology director Sato sells $132k in stock By Investing.com - Investing.com Australia
Insider Sell: Vicki Sato Sells 22,000 Shares of Vir Biotechnology Inc (VIR) - GuruFocus
Vir Biotechnology director Sato sells $132k in stock - Investing.com
Vir Biotechnology Director Sells 22,000 Shares - TradingView
Chmn Sato Sells 22,000 ($132.1K) Of Vir Biotechnology Inc [VIR] - TradingView
Endurance (Cayman) Ltd Svf Sells 61,493 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - MarketBeat
Insider Selling: Vir Biotechnology (NASDAQ:VIR) Major Shareholder Sells 127,938 Shares of Stock - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Shares Down 7.1%What's Next? - MarketBeat
Vir Biotechnology (VIR) Stock Analysis Report | Financials & Insights - Benzinga
Vir Biotechnology Reports Q3 2025 Financial Results and Clinical Progress - MSN
Why analysts remain bullish on Vir Biotechnology Inc. stockJuly 2025 Gainers & Precise Swing Trade Entry Alerts - BỘ NỘI VỤ
Ensign Peak Advisors Inc Increases Position in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology’s Earnings Call: Achievements and Challenges - MSN
Vir Biotechnology (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 227,803 Shares - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Major Shareholder Endurance (Cayman) Ltd Svf Sells 235,971 Shares - MarketBeat
Owner SVF Endurance (Cayman) Ltd Sells 463,774 ($2.9M) Of Vir Biotechnology Inc [VIR] - TradingView
SVF Endurance reports Vir (VIR) insider sales around $6 per share - Stock Titan
H.C. Wainwright Keeps Their Buy Rating on Vir Biotechnology (VIR) - The Globe and Mail
How to manage a losing position in Vir Biotechnology Inc.Weekly Stock Report & AI Enhanced Trade Execution Alerts - newser.com
Is Vir Biotechnology Inc. stock gaining market shareRisk Management & Long Hold Capital Preservation Tips - newser.com
Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference - BioSpace
How Vir Biotechnology Inc. stock reacts to job market dataWeekly Trade Analysis & Consistent Income Trade Ideas - newser.com
What margin trends mean for Vir Biotechnology Inc. stockMarket Trend Summary & Entry Point Confirmation Alerts - newser.com
Vir Biotechnology (NASDAQ:VIR) CFO Sells $37,802.44 in Stock - MarketBeat
Will Vir Biotechnology Inc. stock deliver consistent dividendsTrade Volume Summary & High Win Rate Trade Alerts - newser.com
Why Vir Biotechnology Inc. stock is favored by top institutionsJuly 2025 Momentum & Reliable Intraday Trade Alerts - newser.com
What to do if you’re stuck in Vir Biotechnology Inc.Market Trend Summary & Daily Stock Trend Reports - newser.com
How Vir Biotechnology Inc. stock reacts to oil pricesWeekly Volume Report & Target Return Focused Picks - newser.com
Vir Biotechnology EVP O’Byrne sells $37,782 in shares By Investing.com - Investing.com Nigeria
Vir Biotechnology EVP O’Byrne sells $37,782 in shares - Investing.com
[Form 4] Vir Biotechnology, Inc. Insider Trading Activity - Stock Titan
Vir Biotechnology EVP & CFO Jason O'Byrne Sells Shares - TradingView
CFO O'Byrne Surrenders 6,799 Of Vir Biotechnology Inc [VIR] - TradingView
Finanzdaten der Vir Biotechnology Inc-Aktie (VIR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Vir Biotechnology Inc-Aktie (VIR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SATO VICKI L | Director |
Dec 01 '25 |
Sale |
6.00 |
22,000 |
132,070 |
1,188,391 |
| SVF Endurance (Cayman) Ltd | 10% Owner |
Nov 26 '25 |
Sale |
6.39 |
127,938 |
817,652 |
13,982,271 |
| SVF Endurance (Cayman) Ltd | 10% Owner |
Nov 28 '25 |
Sale |
6.44 |
61,493 |
396,015 |
13,920,778 |
| SVF Endurance (Cayman) Ltd | 10% Owner |
Nov 25 '25 |
Sale |
6.38 |
235,971 |
1,505,495 |
14,110,209 |
| SVF Endurance (Cayman) Ltd | 10% Owner |
Nov 24 '25 |
Sale |
6.15 |
227,803 |
1,400,783 |
14,346,180 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):